Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Sagopilone+ carboplatin · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Sagopilone, 0.5 h infusion | EXPERIMENTAL | Subjects received one infusion (for 0.5 h) of sagopilone every 3 weeks at a dose of 16 mg/m2 (maximum up to 32 mg) for approximately 18 weeks |
| Sagopilone, 3 h infusion | EXPERIMENTAL | Subjects received one infusion (for 3 h) of sagopilone every 3 weeks at a dose of 16 mg/m2 (maximum up to 32 mg) for approximately 18 weeks |
| Name | Type | Description |
|---|---|---|
| Sagopilone (ZK 219477) + carboplatin | DRUG | Chemotherapy for recurrent ovarian cancer |
| Sagopilone (BAY86-5302 , ZK219477) | DRUG | 10.5 mg lyophilized sagopilone per vial |
Inclusion Criteria:- Must have evidence of ovarian cancer measurable by computed tomography (CT) scan or by CA125 blood levels- No radiation therapy in last 4 weeks- No chemotherapy in last 24 weeks - No immunotherapy in last 4 weeks- Good response after previous treatment with carboplatin or cispla...
Sagopilone is an investigational small molecule being studied for the treatment of several cancers, including non-small cell lung cancer, small cell lung cancer, breast cancer, and prostate cancer. It has been evaluated in clinical trials for these oncology indications, though it remains in clinical development and is not approved.
Sagopilone is being developed by Bayer AG, a German pharmaceutical company. Bayer AG is publicly traded under the ticker symbol BAYRY on the OTC market. The company has sponsored clinical trials of Sagopilone in oncology indications.
Sagopilone has completed Phase 2 clinical trials for non-small cell lung cancer and breast cancer, and Phase 1 trials for small cell lung cancer and other neoplasms. It is an investigational drug, meaning it has not been approved by regulatory authorities and remains in clinical development.
Sagopilone has been studied in several completed clinical trials. NCT00160069 was a Phase 2 trial in non-small cell lung cancer with 128 participants in Germany. NCT00313248 was a Phase 2 trial in breast cancer with 65 participants in the US and Canada. NCT00359359 was a Phase 1 trial combining Sagopilone with cisplatin in small cell lung cancer, and NCT00432302 was a Phase 1 mass balance study.
Sagopilone is a distinct investigational agent developed by Bayer AG. No alternative names for Sagopilone have been reported. It is a small molecule chemotherapy agent being evaluated for its safety and efficacy in treating various solid tumors, including lung and breast cancers.